[
  {
    "ts": null,
    "headline": "Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD",
    "summary": "Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placebo Data support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the U.S. and the Europ",
    "url": "https://finnhub.io/api/news?id=f12ee61898907f2e2a4c5933fde75c0c842a107e330ac5a10dd568b28d6cfb8a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741456800,
      "headline": "Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD",
      "id": 133186694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placebo Data support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the U.S. and the Europ",
      "url": "https://finnhub.io/api/news?id=f12ee61898907f2e2a4c5933fde75c0c842a107e330ac5a10dd568b28d6cfb8a"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented At Aad",
    "summary": "Regeneron Pharmaceuticals, Inc. and Sanofi announced Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent in adults with moderate-to-severe bullous...",
    "url": "https://finnhub.io/api/news?id=2cb82dc7961c932174b1da8fda0c184ec0b2785e92b6279d298aa5fa8cacb646",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741438800,
      "headline": "Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented At Aad",
      "id": 133107875,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Regeneron Pharmaceuticals, Inc. and Sanofi announced Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent in adults with moderate-to-severe bullous...",
      "url": "https://finnhub.io/api/news?id=2cb82dc7961c932174b1da8fda0c184ec0b2785e92b6279d298aa5fa8cacb646"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. and Sanofi Presents Positive Results from the Pivotal ADEPT Phase 2/3 trial",
    "summary": "Regeneron Pharmaceuticals, Inc. and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent in adults with moderate-to-severe bullous...",
    "url": "https://finnhub.io/api/news?id=93098218b3c4e1bd265b8f3ec6264627789c2bd83d87c1f96c704b336e57e094",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741438800,
      "headline": "Regeneron Pharmaceuticals, Inc. and Sanofi Presents Positive Results from the Pivotal ADEPT Phase 2/3 trial",
      "id": 133107874,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Regeneron Pharmaceuticals, Inc. and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent in adults with moderate-to-severe bullous...",
      "url": "https://finnhub.io/api/news?id=93098218b3c4e1bd265b8f3ec6264627789c2bd83d87c1f96c704b336e57e094"
    }
  }
]